News|Articles|November 19, 2026

FDA approves venglustat for neurological symptoms of GD3

Fact checked by: Benjamin P. Saylor

Key Takeaways

  • Venglustat is the first FDA-approved treatment for the neurological symptoms of type 3 Gaucher disease, indicated for adults and children weighing at least 15 kg.
  • In the phase 3 LEAP2MONO trial, oral venglustat improved a combined ataxia and cognition measure vs ERT at 52 weeks in patients aged 12 and older, with comparable control of most systemic markers.
SHOW MORE

The FDA approved oral venglustat for neurological symptoms of type 3 Gaucher disease in patients ≥15 kg, based on phase 3 LEAP2MONO data.

Patients with type 3 Gaucher disease (GD3) now have an approved therapy that targets the neurological manifestations of the disease, which enzyme replacement therapy (ERT) has never addressed. On November 18, 2026, the FDA approved venglustat (Infilbray; Genzyme, a Sanofi company) tablets to treat neurological symptoms of GD3 in adults and pediatric patients weighing at least 15 kg.¹

Venglustat is an oral glucosylceramide synthase inhibitor that crosses the blood-brain barrier to reduce glucosphingolipid accumulation in the body and brain.¹ Kyle Diamantas, JD, acting commissioner of the FDA, said the drug's "ability to cross the blood-brain barrier means it can get to the source of the buildup" behind patients' neurological symptoms.¹

LEAP2MONO phase 3 trial design and venglustat efficacy in GD3

The approval is based on LEAP2MONO (NCT05222906), a randomized, double-blind, double-dummy, multicenter trial comparing once-daily oral venglustat with intravenous imiglucerase every 2 weeks over 52 weeks.¹⁻³ The trial enrolled 43 patients aged 12 years or older with GD3 who had received ERT for at least 3 years and had reached therapeutic goals for systemic disease.²˒³

The primary endpoints were change from baseline to week 52 in the modified Scale for Assessment and Rating of Ataxia (mSARA) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index score.² On a global test combining both assessments, patients receiving venglustat improved compared with those receiving ERT (P = .0179).¹˒² Sanofi has not publicly reported effect sizes or CIs. The company reported that venglustat met 3 of 4 key secondary endpoints, with changes in spleen volume, liver volume, and hemoglobin comparable to ERT; it did not detail results for platelet count, the fourth systemic endpoint.²

Venglustat safety profile and psychiatric warnings

In LEAP2MONO, the most common adverse events with venglustat (n = 21) vs ERT (n = 22) were headache (14.3% vs 18.2%), nausea (14.3% vs 4.5%), splenomegaly (14.3% vs 0%), and diarrhea (14.3% vs 0%).² The FDA identified gastrointestinal and mood-related effects as the most frequently reported adverse reactions and noted reports of serious psychiatric events, including suicidal ideation and behavior.¹ Animal studies also suggested possible clouding that could affect vision in younger patients and harm to fetal development with use during pregnancy.¹

Disease burden and unmet need in type 3 Gaucher disease

Gaucher disease is an inherited lysosomal disorder in which a deficient or malfunctioning enzyme prevents the breakdown of glucosphingolipids, which then accumulate in organs and tissues.¹ Data on the neuronopathic forms are sparse; combined prevalence of types 2 and 3 has been estimated at 0.02 to 0.08 per 100,000 population in Europe.⁴ Unlike type 1 disease, GD3 involves the central nervous system, causing progressive problems with balance, coordination, speech, memory, and thinking.¹ ERT controls systemic manifestations, but no therapy has been approved for the neurological symptoms.² The FDA granted venglustat orphan drug designation and priority review.¹

Interpreting venglustat data and open questions for pediatric use

Several caveats temper interpretation. LEAP2MONO was small, and its randomized phase lasted 52 weeks, a short window for a slowly progressive neurological disease; whether the benefit persists is not yet known, and the open-label portion of the study is ongoing.²˒³ Because results were reported as a combined global score with a single P value, the clinical magnitude of change in ataxia and cognition individually is difficult to judge from public data.²

The trial population was also narrow. Participants were aged 12 years or older and already stable on long-term ERT, whereas the approved indication extends to children weighing at least 15 kg.¹˒³ The FDA announcement does not describe the evidence supporting use in younger children or in ERT-naive patients.¹ For pediatric clinicians, the psychiatric risks and the animal signal for vision-related effects in younger patients warrant attention, and the full prescribing information should guide monitoring.¹

References
  1. US Food and Drug Administration. FDA approves first drug to treat neurological symptoms of type 3 Gaucher disease. News release. November 18, 2026. Accessed November 19, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease
  2. Sanofi. Sanofi's venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease. News release. February 2, 2026. Accessed November 19, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-02-06-00-00-3229947
  3. Study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher disease type 3 (LEAP2MONO). ClinicalTrials.gov identifier: NCT05222906. Updated July 2026. Accessed November 19, 2026. https://clinicaltrials.gov/study/NCT05222906
  4. Castillon G, Chang SC, Moride Y. Global incidence and prevalence of Gaucher disease: a targeted literature review. J Clin Med. 2022;12(1):85. doi:10.3390/jcm12010085

Related to this article